Sponsored Symposia

Summary for symposium
TRD and MDSI are debilitating psychiatric conditions with poor outcomes if not treated promptly. 1-3 However, patients in this cohort often undergo multiple treatments with suboptimal effect. 4,5 This symposium will map these challenges and explore the unmet medical needs in this patient population while highlighting the role of the latest treatment strategies.

The first presentation will delve into the evidence around up-to-date treatment strategies, including the growing evidence for esketamine in early line TRD treatment. The next presentation will highlight best practice recommendations for MDSI management, as well as practical insights in translating these into real-world practice. A case study will drive home key messages and illustrate how best practice recommendations could be translated into real-world practice. Further, the expert panel will discuss the nuances of esketamine management within an interactive and engaging Q&A session.

TRD, treatment resistant depression; MDSI, major depression with suicidal ideation; LQD, Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK; ECT, electroconvulsive therapy

1. Swainson J et al. Expert Rev Neurother 2019;19(10):899-911. 2. Jha MK and Mathew SJ. Am J Psychiatry 2023; 180:3:190-99. 3. Neslusan C et al. J Med Econ 2023;26(1):1-10. 4. Vas C et al. Psychiatr Clin North Am 2023; 46(2):261-75. 5. Wang J et al. Front Psychiatry 2025;15:1516846.

EM-181115 | Johnson & Johnson International (Singapore) Pte. Ltd., a Johnson & Johnson company
2 Science Park Drive, #07-13 Ascent, Singapore 118222

EM-182718 | Janssen-Cilag Pty Ltd (ABN: 47 000 129 975), 1-5 Khartoum Road, Macquarie Park, NSW 2113. Phone: 1800 226 334

Date of preparation: May 2025

Chairperson Professor Tianmei (Sixth Hospital of Peking University, Beijing, CN)

Speaker Professor Allan Young (Imperial College London, UK)

Speaker Professor Bernhard Baune (University of Münster, Münster, DE)

Join Professor Leslie Citrome and chairperson Associate Professor Michael Woodward to hear about REXULTI®
Reference: 1. Lee et al. JAMA Neurology 2023;80:2, 6.

Chairperson Associate Professor Michael Woodward, Associate Professor Michael Woodward is Director of Aged Care Research and the lead clinician at the Memory Clinic at Austin Health in Melbourne, Victoria.

Speaker Professor Leslie Citrome Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and Adjunct Professor at the Northwestern Feinberg School of Medicine in Chicago, Illinois.

The Tokyo Metropolitan Institute of Medical Science (TMiMS) began its operations in April 2011 as a brand new institute integrating the formerly independently operated three institutes; the Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Institute of Psychiatry, and Tokyo Metropolitan Institute of Medical Science. Furthermore, the institute was certified as a Public Interest Incorporated Foundation by the Governor of Tokyo. Our institute aims to improve the medical treatment and welfare of citizens in Tokyo through comprehensive and integrative approaches to medical problems the big city is facing. We will collaborate with domestic and international research institutes, hospitals, and companies to develop new and better diagnostic methods, drugs, and therapeutic strategies.

Chairperson Dr. Soichiro Ide, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Chairperson Dr. Yuki Moriya, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Science is entering a decisive open-science era in which transparency, speed, and reproducibility matter as much as novelty and impact. This sponsored luncheon symposium spotlights Neuropsychopharmacology Reports (NPPR) and its expanding network of partner societies as practical avenues for disseminating robust data rapidly and openly.
Tsuyoshi Miyakawa, Editor-in-Chief of NPPR, will outline the journal’s publishing policies and strategies, including (i) rapid editorial handling, (ii) innovative article formats such as Micro Reports, and (iii) acceptance based on scientific soundness rather than perceived “impact,” thereby encouraging the submission of negative or confirmatory findings.
Gregers Wegener, Editor-in-Chief-elect of the International Journal of Neuropsychopharmacology (IJNP), will present the journal’s mission and prospective strategy to advance global neuroscience and education in brain and mental health, and will describe potential partnerships with other journals, including NPPR.
Finally, “Meet the Editors” will bring members of the NPPR editorial team to the stage. Each editor will give a brief self-introduction and share a tip for prospective authors, followed by an open Q&A and discussion.

Chairperson Tsuyoshi Miyakawa, Fujita Health University, Aichi, Japan